4
Changes in Ownership
4D Molecular Therapeutics, Inc. Filed Acc 0000950170-24-002945
Chief Executive Officer sold 102,303 shares at an average $19.15 ($1,959,354)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kirn David Chief Executive Officer | 2023-12-15 | Sale 10b5-1 | −28,632 | $17.27 | $494,432 | 1,230,521 | D |
| Kirn David Chief Executive Officer | 2023-12-18 | Sale 10b5-1 | −4,702 | $18.13 | $85,243 | 1,225,819 | D |
| Kirn David Chief Executive Officer | 2024-01-04 | Sale 10b5-1 | −40,732 | $20.31 | $827,202 | 1,185,087 | D |
| Kirn David Chief Executive Officer | 2024-01-05 | Sale 10b5-1 | −28,104 | $19.56 | $549,804 | 1,156,983 | D |
| Kirn David Chief Executive Officer | 2024-01-05 | Sale 10b5-1 | −133 | $20.11 | $2,674 | 1,156,850 | D |
| Open-market sales · 102,303 sh · avg $19.15 · $1,959,354 | |||||||
Loading xslF345X05/ownership.xml…